You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金升中生製藥(01177.HK)目標價至12元 料上半年收入增長個位數水平
阿思達克 08-06 14:07
中金發表研究報告指,中生製藥(01177.HK)將於月底公布上半年業績,預期收入有單位數增長,符合市場預期。

中金指出,由於疫情及國家帶量採購政策等負面因素,首季肝炎、心血管藥物及其他注射劑銷售均受影響,預期隨著疫情廣泛受控,求醫人數逐漸恢復,未來幾個季度的銷售有望改善,帶量採購的影響也料將消散。

截至8月5日,公司已獲得20種新產品及適應症的申請批准,完成今年目標67%,預計公司未來三年內,每年有超過30種新產品及適應症獲批,加上與創新藥公司及CRO企業的潛在合作,有望進一步豐富研發產品線。

該行維持 2020年除權後每股盈利預測0.17元人民幣不變,將2021年除權後每股盈利預測上調5%至0.2元人民幣,以反映對新產品銷售預期改善,2022年每股盈測則為 0.23元人民幣,維持「跑贏行業」評級,目標價升31%至12元。(gc/u)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account